Orshe

Roche’s Genomics Bet: Roche’s $6 billion hostile bid for DNA-sequencing company Illumina represents a bet that the technology will filter down from academic and government research centers to doctors’ offices and hospitals, the WSJ reports. Roche believes sales of genetic mapping machines will almost double to $2.1 billion by 2015, but some analysts say widespread use is by no means certain.

Three Days in March: The Supreme Court said it will hear five and a half hours of arguments concerning the health-care overhaul law over three days, starting Monday, March 26, the WSJ reports. There will be two hours of argument covering the individual mandate — which requires most Americans to purchase insurance or pay a penalty — scheduled for March 27.

WSJ’s Emily Maltby and Jess Bravin join the News Hub to discuss the legal challenges to President Obama’s health care initiative and the hurdles facing Mary Brown, who has argued strongly against the policy. WSJ photo.

Read more here: One Woman’s Fight Against Obama’s Health Plan/a>

Is donating bone marrow more like giving blood or a kidney?

According to the Ninth U.S. Circuit Court of Appeals, it’s the former. The court ruled today in favor of plaintiffs including a California nonprofit, MoreMarrowDonors.org, that planned a pilot project to offer incentives such as a $3,000 charitable gift or scholarship to help sway more people to donate. (We wrote about compensating bone-marrow donors last year.)

The Obama administration announced yesterday that a dozen more states have crossed the first big threshold in setting up health insurance exchanges — including seven of the states that are suing the administration to overturn the health-care law passed last year.

Managing HIV: New CDC research shows that the majority of patients with HIV in the U.S. aren’t receiving medications and care necessary to control the virus enough to prevent them from passing it to others or impacting their own health, partly because some don’t know they’re infected, the WSJ reports. Only about 28% of the 1.2 million infected people in the U.S. are estimated to get regular care and have their infections under control, the report says.

Pharma Deal: Gilead will pay about $10.4 billion — about $11 billion, including options — for drug developer Pharmasset, the WSJ reports. Pharmasset’s board has approved the deal, which values the company at $137 per share, an 89% premium to Friday’s closing price. Pharmasset said last month it was expanding a trial of a treatment for hepatitis C and Gilead is also pursuing therapies for the disease, the paper says.